Results 21 to 30 of about 6,478 (160)

Intelligent Programmable Membrane Nanosponge for Early Virus Blocking

Advanced Science, EarlyView.
A smart programmable nanosponge (ACNPs) displays high‐density viral receptors on its membrane and encapsulates fusion inhibitors to capture virions at the infection source through competitive binding and blocks their entry through protease inhibition for ultra‐early cascade interception. This modular, mucus‐penetrating platform shifts antiviral defence
Ze Chen, Zhuojun He, Huimin Guo, Min Shi, Ruijing Liang, Lanlan Liu, Yeneng Dai, Qi Zhao, Ke Liu, Yang Zhou, Yang Zhang, Jian Ren, Bin Ju, Quan Fang, Zhaozhen Li, Pengfei Zhao, Mingbin Zheng, Lintao Cai   +17 more
wiley   +1 more source

The anti-COVID-19 drug nirmatrelvir crosses the blood‒brain barrier and exhibits herb–drug pharmacokinetic interactions with Scutellaria baicalensis formulations

Heliyon
Aim of the study: Our hypothesis is that nirmatrelvir can penetrate the blood‒brain barrier and reach effective concentrations in the brain. Furthermore, herbal formulations can help maintain nirmatrelvir levels in the body, suggesting potential ...
Wan-Hsin Lee, Yen-Ying Kung, Chung-Kai Sun, Chun-Hao Chang, Wen-Ya Peng, Lie-Chwen Lin, Chung-Hua Hsu, Muh-Hwa Yang, Tung-Hu Tsai   +8 more
doaj   +1 more source

Bioequivalence study of generic nirmatrelvir in healthy volunteers

Фармация и фармакология (Пятигорск), 2023
Nirmatrelvir is an antiviral drug that, in combination with ritonavir, is an effective agent for the etiotropic therapy of patients with mild to moderate COVID-19.The aim of the study was to evaluate bioequivalence of the generic drug nirmatrelvir ...
R. A. Oseshnyuk, A. G. Nikiforova, A. Yu. Boroduleva, P. D. Sobolev, S. A. Lesnichuk, B. B. Garyaev, A. A. Abramova, V. G. Mozgovaya, O. V. Filon, A. V. Zinkovskaya, A. N. Dolgorukova, E. K. Khanonina, V. G. Ignatiev, M. Yu. Samsonov   +13 more
doaj   +1 more source

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M. M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, on behalf of RECOVER‐Adult   +18 more
wiley   +1 more source

Patient Experiences With Nirmatrelvir/Ritonavir for COVID-19 in a Collaborative Care Model: A Cross-Sectional Study on Self-Management, Information, and Medication Impact

Journal of Patient Experience
In response to the COVID-19 pandemic, nirmatrelvir/ritonavir was approved as the first per os treatment to prevent severe disease progression. This study explores patients’ self-management of nirmatrelvir/r and its impact on their long-term medications ...
Beatriz Santos MS, Maeva Rousseau MS, Ralitza Gauthier PhD, Alexandra Calmy MD, PhD, Marie P. Schneider PhD   +4 more
doaj   +1 more source

The effect of anti‐seizure medications on exposure to statins: A systematic review and meta‐analysis

Epileptic Disorders, EarlyView.
Abstract Objectives Antiseizure medications (ASMs) can reduce the efficacy of statin treatment, partly due to reduction in statin concentrations. In this systematic review and network meta‐analysis (NMA), we compared the effects of ASMs and the prototypical enzyme inducer rifampin on statin exposure.
Sharon Valiyev Huino, Hagar Cohen, Bruria Hirsh Raccah, Tomer Ben‐Shushan, Ilan Matok, Sara Eyal   +5 more
wiley   +1 more source

Model‐Based Tacrolimus Dosing Using the Population Pharmacokinetic Analysis Under the Nirmatrelvir/Ritonavir Therapy

CPT: Pharmacometrics & Systems Pharmacology
Nirmatrelvir/ritonavir is an antiviral agent used against severe acute respiratory syndrome coronavirus 2 infection and inhibits cytochrome P450 3A and P‐glycoprotein.
Kotaro Itohara, Yoshiki Katada, Takahiro Hatayama, Toshiaki Igarashi, Jiro Ogura, Tomoki Fukushima, Shingo Yamazaki, Masato Homma, Takashi Niwa, Yoshiaki Kato, Nanae Yamamoto, Hideyuki Terazono, Hideo Shiohira, Tomohiro Terada, Ikuko Yano   +14 more
doaj   +1 more source

A real‐world analysis of AI chatbot performance for medicines information enquiries

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background The provision of medicines information (MI) services requires interpretation and clinical judgement of complex scenarios by pharmacists. To date, few studies have assessed the performance of artificial intelligence (AI) chatbots to assist pharmacists providing MI advice.
Duncan Yorkston, Tracey Borrie, Paul Chin   +2 more
wiley   +1 more source

Evolution of the SARS‐CoV‐2 Main Protease Under Fitness Constraints Imposed by Folding Stability and Activity

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) continues to evolve and diversify, leading to the emergence of immune‐evasive variants and underscoring the need for complementary antiviral strategies targeting conserved viral machinery. In this context, the main protease (Mpro) represents a potential therapeutic target because
David Ferreiro, Miguel Arenas
wiley   +1 more source

Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study

Annals of Medicine
Background The effectiveness of nirmatrelvir–ritonavir has mainly been shown in non-hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19).
Xiaobo Han, Chenglong Li, Xin Yuan, Junchang Cui, Zhihai Han, Jiguang Meng, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Wei Chen, Junchen Xiong, Dahui Zhao, Xinxin Zhang, Xinjie Han, Haibo Cheng, Zhongkuo Yu, Yinghan Shi, Wuxiang Xie, Lixin Xie   +24 more
doaj   +1 more source